Hilton Pharma Acquires Methycobal and Myonal from Eisai

The Competition Commission of Pakistan (CCP) has granted permission to M/s Hilton Pharma Pvt Ltd to acquire two pharmaceutical products, 'Methycobal and Myonal,' from M/s Eisai Co. Ltd, a renowned pharmaceutical company based in Tokyo. This acquisition, facilitated through an Asset Purchase Agreement (APA), involves the transfer of trademarks, know-how, and records of the products for manufacturing and distribution in Pakistan.

Hilton Pharma, a leading pharmaceutical company established in 1989, specializes in producing and supplying medicinal products in Pakistan. It holds authorization from the Drug Regulatory Authority of Pakistan for pharmaceutical manufacturing. On the other hand, Eisai Co. Ltd, a Japanese pharmaceutical giant, is globally acknowledged for its expertise in research, manufacturing, and marketing of prescription medicines.

The CCP's evaluation primarily focused on the 'Pharmaceutical – Myonal and Methycobal' market segment. It was observed that Hilton Pharma is currently engaged in manufacturing and selling these products under a License Agreement, which will be discontinued post-acquisition. Despite its existing market presence, the acquisition is not expected to significantly alter Hilton Pharma's market position, ensuring a competitive market environment.

This acquisition is poised to introduce additional expertise to bolster local pharmaceutical production in Pakistan. By endorsing this transaction, the CCP aims to foster self-reliance and offer advanced, locally manufactured pharmaceutical options to enhance the country's pharmaceutical sector.

The approval of the acquisition by Hilton Pharma Pvt Ltd marks a significant step towards strengthening the local pharmaceutical industry in Pakistan. This move not only promotes self-sufficiency but also paves the way for enhanced pharmaceutical offerings tailored to the needs of the Pakistani market.